NervGen Pharma Corp. Common stock (NGEN) Earnings Analysis

NervGen Pharma Corp. Common stock (NGEN) next reports earnings on 2026-08-21, consensus EPS -0.09 USD. Last quarter (2026-05-18) it beat with EPS -0.01453 USD vs -0.07395 USD est (+80.4%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -8.41.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NGEN next report earnings?

Next earnings date2026-08-21
Consensus EPS estimate-0.09 USD
Revenue estimate0.00B

NGEN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-18-0.01453 USD-0.07395 USD+80.4%Beat
2026-03-31-0.25796 USD-0.06376 USD-304.6%Miss

Beat rate: 1/2 (50%) over reported quarters with consensus data.

NGEN valuation and analyst view

Trailing P/E-8.41
Trailing EPS-0.603 USD
Price / book108.37
Dividend yield0.00%
Market cap0.14B
Analyst consensusBuy (1 buy / 0 hold / 0 sell)
Avg price target12 USD

Related research pages

Frequently asked questions

When is NervGen Pharma Corp. Common stock (NGEN)'s next earnings date?

NervGen Pharma Corp. Common stock is next scheduled to report on 2026-08-21, with a consensus EPS estimate of -0.09 USD and revenue estimate of 0.00B.

Did NGEN beat earnings last quarter?

In its 2026-05-18 report, NGEN posted EPS of -0.01453 USD versus a -0.07395 USD estimate — a beat of 80.4%.

What is NGEN's earnings track record?

Over the last 2 reported quarters with consensus data, NGEN beat estimates 1 times (50%).

What is NGEN's current P/E ratio and EPS?

NGEN trades at a trailing P/E of -8.41 on trailing EPS of -0.6030007791377197 USD.

What do analysts rate NGEN?

Analyst consensus is "Buy" across 1 ratings (0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 12 USD.